EMMAC and Imperial College London manuscript to be published in peer-reviewed Cannabis and Cannabinoid Research Journal
4 July 2019, London. EMMAC Life Sciences Ltd, the European independent medical cannabis company, announces that the manuscript, “A comprehensive patient and public involvement programme evaluating perception of cannabis-derived medicinal products in the treatment of acute postoperative pain, nausea and vomiting using a qualitative thematic framework” has been published in ‘Cannabis and Cannabinoid Research’, the only peer-reviewed journal dedicated to the scientific, medical and psychosocial exploration of clinical cannabis, cannabinoids and the endocannabinoid system, and the official journal of the International Cannabinoid Research Society (ICRS).
The manuscript is part of EMMAC’s collaboration with Imperial College London, forged to deliver a long-term comprehensive research programme designed to inform and shape the future of the medical cannabis therapeutic industry. The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.
This study represents the first stage of the clinical trial process and was carried out with the Imperial Clinical Trials Unit (ICTU). It represents comprehensive patient and public involvement activities, and prior to peer reviewed publication these data were selected for presentation at the 5th International Emerald Conference in San Diego in February 2019, EMMAC Poster Emerald Conference.
Dr Mikael Sodergren, Research Director at EMMAC, commented: “At EMMAC we believe the growth of medical cannabis must be underpinned by the most robust science, and we aim to publish and present all research through peer-reviewed journal publications and recognised international conferences. We look forward to sharing more research as EMMAC continues to work with Imperial and leading European institutions to advance the industry’s understanding of the medical benefits of cannabis.”
EMMAC is the European independent medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.
About Imperial College London
Imperial College London is one of the world’s leading universities. The College’s 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.
Founded in 1907, Imperial builds on a distinguished past – having pioneered penicillin, holography and fibre optics – to shape the future. Imperial researchers work across disciplines to improve health and wellbeing, understand the natural world, engineer novel solutions and lead the data revolution. This blend of academic excellence and its real-world application feeds into Imperial’s exceptional learning environment, where students participate in research to push the limits of their degrees.
Imperial is the UK’s most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK’s most innovative university because of its exceptional entrepreneurial culture and ties to industry.
For scientific enquiries please contact [email protected]
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz Tel: +44 (0) 20 7466 5000
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Ltd. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Ltd assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.